- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT05024175
A CARv3-TEAM-E T-sejtekkel kezelt alanyok hosszú távú nyomon követése
This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.
No investigational treatment will be administered in this study.
The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.
Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).
Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.
Tanulmány típusa
Beiratkozás (Becsült)
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Matthew J Frigault, MD
- Telefonszám: 617-643-6175
- E-mail: mfrigault@mgb.org
Tanulmányi helyek
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Toborzás
- Massachusetts General Hospital
-
Kutatásvezető:
- Matthew J Frigault, MD
-
Kapcsolatba lépni:
- Matthew J Frigault, MD
- Telefonszám: (617) 724-4000
- E-mail: mfrigault@mgb.org
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit
Leírás
Inclusion Criteria:
Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.
Subjects meeting the following criteria are eligible for study participation:
- Provision of voluntary written informed consent by subject
- CAR T cells were administered in HCC IRB or MGB IRB corresponding main study
Exclusion Criteria:
Subjects meeting the following criterion are to be excluded from study participation:
- Subject unable to comply with study requirements
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Megfigyelési modellek: COHORT
- Időperspektívák: PROSPECTIVE
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
|---|---|
|
CAR T cells
|
CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol Tumor Biopsy per protocol Blood Test per protocol |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Overall Survival
Időkeret: 1 month
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
1 month
|
|
Overall Survival
Időkeret: 6 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
6 months
|
|
Overall Survival
Időkeret: 12 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
12 months
|
|
Overall Survival
Időkeret: 24 months
|
defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive |
24 months
|
|
Progresison Free Survival
Időkeret: 1 month
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
1 month
|
|
Progresison Free Survival
Időkeret: 6 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
6 months
|
|
Progresison Free Survival
Időkeret: 12 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
12 months
|
|
Progresison Free Survival
Időkeret: 24 months
|
PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
24 months
|
|
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
Időkeret: Up to 15 Years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
Up to 15 Years
|
|
New incidence of a hematologic disorder
Időkeret: up to 15 years
|
An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases. |
up to 15 years
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
Időkeret: up to 15 years
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) |
up to 15 years
|
|
Vector-derived RCL
Időkeret: baseline and in 3 months, 6 months, and annually up to 15 years
|
Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA). |
baseline and in 3 months, 6 months, and annually up to 15 years
|
|
Assessment of CAR T cells persistence by VCN in peripheral blood
Időkeret: baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence |
baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
|
|
Progression-free Survival
Időkeret: From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment. |
From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
|
|
Overall Survival
Időkeret: From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
The time from post-CAR T cells infusion to the date of death. |
From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Matthew J Frigault, MD, Massachusetts General Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 20-721
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD megosztási időkeret
Data can be shared no earlier than 1 year following the date of publication
IPD-megosztási hozzáférési feltételek
Contact the Partners Innovations team at http://www.partners.org/innovation
Az IPD megosztását támogató információ típusa
- STUDY_PROTOCOL
- NEDV
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .